SBIR Phase I: Production of Fullerene Radiopharmaceuticals Using Nuclear Recoil

SBIR 第一阶段：利用核反冲生产富勒烯放射性药物

• 批准号: 0215240
• 负责人: John Alford
• 金额: $ 10万
• 依托单位: TDA Research, Inc
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-07-01 至 2002-12-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=0215240&HistoricalAwards=false
• 关键词: SBIR; Phase; Production; Fullerene; Radiopharmaceuticals

This Small Business Innovation Research (SBIR) Phase I Projectproposes to develop methods for producing fullerene radioisotope carriers using the nuclear recoil implantation method. A persistent problem in the safe delivery of radioisotopes to cancer tissue is the premature leakage of the radioisotope and the damage it causes to healthy tissues such as bone marrow. Currently, when radioactive metals are used in the body for diagnostic or therapeutic applications, organic chelates must be employed as carriers for the metal atom. However, current chelates do not bind with 100% efficiency, and potentially toxic radioactive metal atoms can be lost in vivo. Because of their unique cage structure, fullerenes do not suffer this deficiency and offer a novel alternative method for entrapping radioisotopes and producing labeled compounds useful for medical imaging and therapy.The commercial applications of this project are in the area of cancer radioimmunotherapy. Given the recent advances in the design of monoclonal antibodies for targeting cancer and in the clinical successes of several new radioimmunotherapy treatments, the field of radioimmunotherapy is currently poised for rapid growth and commercialization. A superior radioisotope carrier would be a welcome addition to the current arsenal of radiopharmaceuticals.

本小企业创新研究（SBIR）第一阶段项目提出开发使用核反冲注入法生产富勒烯放射性同位素载体的方法。在将放射性同位素安全递送到癌组织中的一个持续存在的问题是放射性同位素的过早泄漏及其对健康组织如骨髓造成的损害。目前，当放射性金属在体内用于诊断或治疗应用时，必须采用有机螯合物作为金属原子的载体。然而，目前的螯合物不能以100%的效率结合，并且潜在有毒的放射性金属原子可能在体内丢失。由于其独特的笼状结构，富勒烯没有遭受这一缺陷，并提供了一种新的替代方法，用于捕获放射性同位素和生产标记化合物用于医学成像和治疗。鉴于最近在设计用于靶向癌症的单克隆抗体方面的进展以及几种新的放射免疫疗法治疗的临床成功，放射免疫疗法领域目前正准备快速增长和商业化。一种上级放射性同位素载体将是目前放射性药物库中受欢迎的补充。